

# Characterizing Perceived Physical Fatigability in Nusinersen-treated SMA

NCT06955897

---

**Status** RECRUITING  
**Sponsor** Columbia University  
**Enrollment** 45 participants

## Key Eligibility Criteria

---

### Inclusion (2)

- All types of 5qSMA (homozygous deletion or point mutation of the SMN1 gene and any number of SMN2 copies)
- Receiving a stable dosing regimen of 12mg nusinersen for at least 6 months

### Exclusion (3)

- An injury or surgery within the previous 3 months that would impact their ability to perform in-clinic function and/or fatigability assessments
- Enrolled in an ongoing clinical trial, or extension study, expanded access program, or long-term registry of an investigational or recently approved medication
- Receiving adjuvant and/or dual therapy (e.g., muscle-targeted, NMJ, or symptomatic treatments)

## Locations (1 total)

---

Columbia University Irving Medical Center, New York, New York, United States